Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07391566 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation

Name: LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation — clinical trial record (NCT07391566)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorLuye Pharma Group Ltd.

Started2026-03-31

View on ClinicalTrials.gov ↗

Luye Pharma Group Ltd.

16 trials monitored

See all monitored trials

Colorectal Cancer

2,904 trials monitored

See 127 trials at risk

This study is consist of phase 1b (dose escalation + safety run-in) and phase 2 (randomized, controlled). Phase 1b is planned to evaluate the safety and tolerability of LPM6690176 capsule in combination with chemotherapy and Bevacizumab in patients with RAS mutant metastatic colorectal cancer (mCRC), to observe the dose-limiting toxicity (DLT), and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D); Phase 2 is planned to preliminarily evaluate the efficacy of LPM6690176 capsule in combination with chemotherapy + Bev vs. chemotherapy + Bev in patients with previously untreated, RAS mutant mCRC.

Trial Details

NCT Number	NCT07391566
Lead Sponsor	Luye Pharma Group Ltd.
Conditions	Metastatic Colorectal Cancer (mCRC)
Enrollment	99 participants
Start Date	2026-03-31
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-06